Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

NCT02205047 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT02205047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02205047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2015
Completion date
December 31, 2024
Enrollment
172 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor (egfr) protein overexpression, malignant neoplasm of cardio-esophageal junction of stomach, malignant neoplasm of stomach